Literature DB >> 30566565

TRIM29 prevents hepatocellular carcinoma progression by inhibiting Wnt/β-catenin signaling pathway.

Mingxing Xu1, Jingxiong Hu1, Boxuan Zhou1, Yuesi Zhong1, Nan Lin1, Ruiyun Xu1.   

Abstract

TRIM29 plays an important role in many neoplasms. In this study, we aimed to elucidate its role in hepatocellular carcinoma (HCC) and explore the corresponding potential mechanism. The expression level of TRIM29 in HCC samples and hepatoma cell lines was detected. We found that TRIM29 was down-regulated in clinical HCC samples and cultured hepatoma cell lines by western blot analysis and quantitative polymerase chain reaction. In addition, we demonstrated that higher TRIM29 expression was associated with higher differentiation grade of HCC. To explore the effect of TRIM29 on hepatoma cells and its possible mechanisms, TRIM29-knockdown and overexpression cell models were constructed. The results showed that the depletion of TRIM29 promoted liver cancer cell proliferation, clone formation, migration and invasion in vitro probably through the Wnt/β-catenin signaling pathway. This study revealed the inhibitory roles of TRIM29 in HCC and the possible mechanisms.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30566565     DOI: 10.1093/abbs/gmy151

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  11 in total

Review 1.  The TRIM proteins in cancer: from expression to emerging regulatory mechanisms.

Authors:  A Mohammadi; M S Pour Abbasi; S Khorrami; S Khodamoradi; Z Mohammadi Goldar; F Ebrahimzadeh
Journal:  Clin Transl Oncol       Date:  2021-10-13       Impact factor: 3.405

2.  Clinical significance of TRIM29 expression in patients with gastric cancer.

Authors:  Javad Farhadi; Jamshid Mehrzad; Hassan Mehrad-Majd; Alireza Motavalizadehkakhky
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2022

Review 3.  The Tripartite Nexus: Autophagy, Cancer, and Tripartite Motif-Containing Protein Family Members.

Authors:  Michael A Mandell; Bhaskar Saha; Todd A Thompson
Journal:  Front Pharmacol       Date:  2020-03-11       Impact factor: 5.810

4.  Long non‑coding RNA TP73‑AS1 accelerates the progression and cisplatin resistance of non‑small cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA‑34a‑5p.

Authors:  Shunxiang Luo; Ming Shen; Hui Chen; Weiwei Li; Cong Chen
Journal:  Mol Med Rep       Date:  2020-09-01       Impact factor: 2.952

Review 5.  TRIM29 in Cutaneous Squamous Cell Carcinoma.

Authors:  Che-Yuan Hsu; Teruki Yanagi; Hideyuki Ujiie
Journal:  Front Med (Lausanne)       Date:  2021-12-20

6.  miR-34c-5p mediates the cellular malignant behaviors of oral squamous cell carcinoma through targeted binding of TRIM29.

Authors:  Yuchen Shen; Changsheng Sun; Bowen Zhao; Haobing Guo; Jianhao Li; Yanyun Xia; Miaomiao Liu; Songlin Piao; Wuliji Saiyin
Journal:  Ann Transl Med       Date:  2021-10

7.  A hybrid feature selection algorithm and its application in bioinformatics.

Authors:  Yangyang Wang; Xiaoguang Gao; Xinxin Ru; Pengzhan Sun; Jihan Wang
Journal:  PeerJ Comput Sci       Date:  2022-03-22

Review 8.  Tumor suppressor p53 cross-talks with TRIM family proteins.

Authors:  Juan Liu; Cen Zhang; Xue Wang; Wenwei Hu; Zhaohui Feng
Journal:  Genes Dis       Date:  2020-07-16

9.  TRIM29 inhibits miR-873-5P biogenesis via CYTOR to upregulate fibronectin 1 and promotes invasion of papillary thyroid cancer cells.

Authors:  Tong Wu; Da-Lin Zhang; Jia-Mei Wang; Jing-Yi Jiang; Xin Du; Xiao-Yan Zeng; Zhen-Xian Du
Journal:  Cell Death Dis       Date:  2020-09-29       Impact factor: 8.469

10.  Identification of key genes and pathways for melanoma in the TRIM family.

Authors:  YiJun Xia; Jun Zhao; Chunjun Yang
Journal:  Cancer Med       Date:  2020-10-28       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.